Sunday - December 22, 2024

Treatment of Uveitis With Endoplasmic Reticulum Aminopeptidase 1 (ERAP1) Inhibitors

2024-12-03

ALEXANDRIA, Virginia, Dec. 3 -- REGENERON PHARMACEUTICALS, INC., Tarrytown, New York has been assigned a patent (No. US 12157891 B2, initially filed Oct. 13, 2022) developed by ten inventors Sahar Gelfman, Tarrytown, New York; Ann Ligocki, Tarrytown, New York; Giovanni Coppola, Tarrytown, New York; Aris Baras, Tarrytown, New York; Arden Moscati, Tarrytown, New York; Eli A. Stahl, Tarrytown, New York; Carmelo Romano, Tarrytown, New York; Santiago Mendez Huergo, Tarrytown, New York; Jonathan Weyne . . .

Information Request Form

Name:
Category that best fits the type of business or agency you are affiliated with:	Government Newspaper / Media Business Public Policy Individual / Student Educators
Company Name:
Email:
Phone:
State:

I'd like to have a copy of this article mailed to me.

To also receive a free sample of other Targeted News products check the appropriate boxes below.
Golf Handicap site (FairwayFiles.com)
Products marked with ** can be customized by keywords or areas of interest. If you select them please specify your keywords in the box below:

If we need to contact you please specify your preferred contact method. Have a representative contact me by phone
Have a representative contact me via email

Additonal questions or comments:

Click here for more information or a free trial

Existing Customer Login

Treatment of Uveitis With Endoplasmic Reticulum Aminopeptidase 1 (ERAP1) Inhibitors

Information Request Form

Copyright Targeted News Service 2024